Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Telcyta: Phase II

Interim results from an ongoing U.S. Phase II trial of Telcyta as monotherapy

Read the full 135 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE